Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Nuclear Medicine
Erschienen in: Annals of Nuclear Medicine 6/2020

15.04.2020 | Original Article

Prognostic value of pretreatment tumor-to-blood standardized uptake ratio (SUR) in rectal cancer

verfasst von: Gokce Belge, Cem Bilgin, Guven Ozkaya, Sedat Giray Kandemirli, Eray Alper

Erschienen in: Annals of Nuclear Medicine | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The prognostic value of SUV on pretreatment F-18 FDG PET/CT imaging in patients with rectal cancer is a matter of debate. SUR is of prognostic value for survival in different cancers. In this study, we aimed to examine the potential prognostic value of SUR and other parameters in pretreatment F-18 FDG PET/CT for non-metastatic rectal cancer.

Methods

One hundred four non-metastatic rectal cancer patients who underwent pretreatment PET/CT between March 2012 and January 2018 were included in the study. Firstly, SUVmax, SUVmean, MTV, and TLG were calculated semi-automatically at the workstation. SUR was calculated as the ratio of tumor SUVmax to thoracic aorta blood SUVmean. Univariate Cox regression and Kaplan–Meier analysis were used to evaluate overall survival (OS), progression free survival (PFS), and local recurrence (LR). Then, multivariate Cox regression analysis, which included the parameters that were significant in the univariate analysis, was performed.

Results

Multivariate Cox regression analysis revealed that SUR was a prognostic factor for PFS. Age and T stage were prognostic factors for both OS and PFS. MTV was found to be independent risk factors for OS.

Conclusions

In our study, SUR was the only F-18 FDG PET/CT parameter found to be significant for PFS. The development of new parameters can increase the prognostic value of F-18 FDG PET/CT.
Literatur
1.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.PubMed
2.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.PubMed
4.
Valentini V, Coco C, Cellini N, Picciocchi A, Fares MC, Rosetto ME, et al. Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. Int J Radiat Oncol Biol Phys. 2001;51(2):371–83.PubMed
5.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–40.PubMed
6.
Park J, Chang KJ, Seo YS, Byun BH, Choi JH, Moon H, et al. Tumor SUVmax normalized to liver uptake on 18F-FDG PET/CT predicts the pathologic complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Nucl Med Mol Imaging. 2014;48(4):295–302.PubMedPubMedCentral
7.
Kim SJ, Chang S. Volumetric parameters changes of sequential 18F-FDG PET/CT for early prediction of recurrence and death in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. Clin Nucl Med. 2015;40(12):930–5.PubMed
8.
Goldberg N, Kundel Y, Purim O, Bernstine H, Gordon N, Morgenstern S, et al. Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18F-FDG PET-CT imaging. A prospective clinical study. Radiat Oncol. 2012;7(1):124.PubMedPubMedCentral
9.
Rymer B, Curtis NJ, Siddiqui MR, Chand M. FDG PET/CT can assess the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy: evidence from meta-analysis and systematic review. Clin Nucl Med. 2016;41(5):371–5.PubMed
10.
Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73(11):1151–7.PubMed
11.
Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg. 2006;82(2):391–5.PubMed
12.
Chung HW, Lee EJ, Cho YH, Yoon SY, So Y, Kim SY, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol. 2010;136(12):1929–35.PubMed
13.
Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, et al. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115(14):3196–203.PubMed
14.
Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, et al. Using positron emission tomography with [18F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001;3(3):189–95.PubMedPubMedCentral
15.
Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med. 2007;48(5):771–5.PubMed
16.
Hui W, Jinming Z, Jiahe T, Baolin Q, Tianran L, Yingmao C, et al. Using dual-tracer PET to predict the biologic behavior of human colorectal cancer. J Nucl Med. 2009;50(11):1857–64.
17.
Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST507, et al. Prognostic value of 18-fluorodeoxyglucose positron emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol. 2012;18(36):5072–7.PubMedPubMedCentral
18.
van den Hoff J, Oehme L, Schramm G, Maus J, Lougovski A, Petr J, et al. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG. EJNMMI Res. 2013;3(1):1–8.
19.
Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3(1):1–7.PubMed
20.
Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985;5(4):584–90.PubMed
21.
Wong WH, Hicks K. A clinically practical method to acquire parametric images of unidirectional metabolic rates and blood spaces. J Nucl Med. 1994;35:1206–12.PubMed
22.
Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med. 1996;37(2):371–4.PubMed
23.
Sundaram SK, Freedman NM, Carrasquillo JA, Carson JM, Whatley M, Libutti SK, et al. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach. J Nucl Med. 2004;45(8):1328–33.PubMed
24.
Bütof R, Hofheinz F, Zöphel K, Stadelmann T, Schmollack J, Jentsch C, et al. Prognostic value of pretherapeutic tumor-to-blood standardized uptake ratio in patients with esophageal carcinoma. J Nucl Med. 2015;56(8):1150–6.PubMed
25.
Shin S, Pak K, Kim IJ, Kim BS, Kim SJ. Prognostic value of tumor-to-blood standardized uptake ratio in patients with resectable non-small-cell lung cancer. Nucl Med Mol Imaging. 2017;51(3):233–9.PubMed
26.
Kostakoglu L, Chauvie S. Metabolic tumor volume metrics in lymphoma. Semin Nucl Med. 2018;48(1):50–66.PubMed
27.
Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195(2):310–20.PubMed
28.
Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, et al. Variance of standardized uptake values for FDG-PET/CT greater in clinical practice than under ideal study settings. Clin Nucl Med. 2013;38(3):175–82.PubMedPubMedCentral
29.
Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, et al. Repeatability of 18F-FDG PET/CT in advanced non–small cell lung cancer: prospective assessment in 2 multicenter trials. J Nucl Med. 2015;56(8):1137–43.PubMedPubMedCentral
30.
Hofheinz F, Apostolova I, Oehme L, Kotzerke J, van den Hoff J. Test–retest variability in lesion SUV and lesion SUR in 18F-FDG PET: an analysis of data from two prospective multicenter trials. J Nucl Med. 2017;58(11):1770–5.PubMedPubMedCentral
31.
Hofheinz F, Van den Hoff J, Steffen IG, Lougovski A, Ego K, Amthauer H, et al. Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET. EJNMMI Res. 2016;6(1):53.PubMedPubMedCentral
32.
de Geus-Oei LF, Visser EP, Krabbe PF, van Hoorn BA, Koenders EB, Willemsen AT, et al. Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. J Nucl Med. 2006;47(6):945–9.PubMed
33.
Takahashi Y, Oriuchi N, Otake H, Endo K, Murase K. Variability of lesion detectability and standardized uptake value according to the acquisition procedure and reconstruction among five PET scanners. Ann Nucl Med. 2008;22(6):543–8.PubMed
34.
Toriihara A, Yoshida K, Umehara I, Shibuya H. Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging. Ann Nucl Med. 2011;25(3):173–8.PubMed
35.
Minamimoto R, Terauchi T, Jinnouchi S, Yoshida T, Tsukamoto E, Shimbo T, et al. Observer variation study of the assessment and diagnosis of incidental colonic FDG uptake. Ann Nucl Med. 2013;27(5):468–77.PubMed
36.
Minamimoto R, Takahashi N, Inoue T. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues. Ann Nucl Med. 2007;21(4):217–22.PubMed
37.
Toriihara A, Kitazume Y, Nishida H, Kubota K, Nakadate M, Tateishi U. Comparison of FDG-PET/CT images between chronic renal failure patients on hemodialysis and controls. Am J Nucl Med Mol Imaging. 2015;5(2):204–11.PubMedPubMedCentral
38.
Ouyang ML, Tang K, Xu MM, Lin J, Li TC, Zheng XW. Prediction of occult lymph node metastasis using tumor-to-blood standardized uptake ratio and metabolic parameters in clinical N0 lung adenocarcinoma. Clin Nucl Med. 2018;43(10):715–20.PubMed
39.
Geets X, Lee JA, Bol A, Lonneux M, Grégoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging. 2007;34(9):1427–38.PubMed
40.
Vallius T, Hynninen J, Kemppainen J, Alves V, Auranen K, Matomäki J, et al. 18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer. Eur J Nucl Med Mol Imaging. 2018;45(7):1224–32.PubMed
41.
Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(2):241–51.PubMed
42.
Chen MK, Chen CM, Lee MC, Chen LS, Chen HC. Primary tumor volume is an independent predictor of outcome within pT4a-staged tongue carcinoma. Ann Surg Oncol. 2011;18(5):1447–52.PubMed
43.
Timmermans AJ, Lange CA, de Bois JA, van Werkhoven E, Hamming-Vrieze O, Hilgers FJ, et al. Tumor volume as a prognostic factor for local control and overall survival in advanced larynx cancer. Laryngoscope. 2016;126(2):60–7.
44.
Tayyab M, Razack A, Sharma A, Gunn J, Hartley JE. Correlation of rectal tumor volumes with oncological outcomes for low rectal cancers: does tumor size matter? Surg Today. 2015;45(7):826–33.PubMed
45.
Torricelli P. Rectal cancer staging. Surg Oncol. 2007;16(1):49–50.
46.
O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–5.PubMed
47.
O'Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28(6):558–62.PubMed
48.
Lee PY, Fletcher WS, Sullivan ES, Vetto JT. Colorectal cancer in young patients: characteristics and outcome. Am Surg. 1994;60(8):607–12.PubMed
49.
Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP. Large bowel cancer: surgical pathology and its relationship to survival. Br J Surg. 1984;71(8):604–10.PubMed
50.
Fairley TL, Cardinez CJ, Martin J, Alley L, Friedman C, Edwards B, et al. Colorectal cancer in U.S. adults younger than 50 years of age, 1998–2001. Cancer. 2006;107(5):1153–61.PubMed
51.
O’Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187(3):343–8.PubMed
Metadaten
Titel
Prognostic value of pretreatment tumor-to-blood standardized uptake ratio (SUR) in rectal cancer
verfasst von
Gokce Belge
Cem Bilgin
Guven Ozkaya
Sedat Giray Kandemirli
Eray Alper
Publikationsdatum
15.04.2020
Verlag
Springer Singapore
Erschienen in
Annals of Nuclear Medicine / Ausgabe 6/2020
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-020-01465-8

Weitere Artikel der Ausgabe 6/2020

Annals of Nuclear Medicine 6/2020 Zur Ausgabe

Original Article

High-dose 131I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan

Original Article

Retrospective correlation of 68ga-psma uptake with clinical parameters in prostate cancer patients undergoing definitive radiotherapy

Original Article

Assessing the feasibility of NaF-PET/CT versus FDG-PET/CT to detect abdominal aortic calcification or inflammation in rheumatoid arthritis patients

Original Article

Radiation exposure in nurses during care of 131I-MIBG therapy for pediatric patients with high-risk neuroblastoma

Original Article

A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index

Short Communication

Ciliated muconodular papillary tumor of the lung: 18F-FDG PET/CT findings of 15 cases